Search results
Results from the WOW.Com Content Network
The Medication Appropriateness Tool for Comorbid Health conditions during Dementia (MATCH-D) criteria supports clinicians to manage medication use specifically for people with dementia without focusing only on the management of the dementia itself.
The recommended adult dose contains: Acetaminophen (650 mg/30 mL) (pain reliever/fever reducer) Dextromethorphan (30 mg/30 mL) (cough suppressant) Doxylamine succinate (12.5 mg/30 mL) (antihistamine/hypnotic) Alcohol (10% by volume) The LiquiCap capsule version has the following active ingredients per pill, half the recommended adult dose:
Each formulation also varies per dose. When purchasing over-the-counter medications, avoid purchasing multiple products with acetaminophen ingredients. The suggested maximum daily intake of acetaminophen is limited to <4 grams (4,000 mg) daily in adults or <2.6g (2,600 mg) daily in children <12 years of age to reduce the risk of liver damage.
Dextromethorphan, sold under the brand name Robitussin among others, is a cough suppressant used in many cough and cold medicines. [6] In 2022, the US Food and Drug Administration (FDA) approved the combination dextromethorphan/bupropion to serve as a rapid-acting antidepressant in people with major depressive disorder.
Cold syrup overdose has been linked to visual and auditory hallucinations as well as rapid involuntary jaw, tongue, and eye movements in children. [ medical citation needed ] Decongestants are possibly harmful to people with high blood pressure or a heart disease because these substances can constrict the blood vessels.
Ketamine’s antidepressant effects are part of what prompted researchers to explore other drugs that target glutamate—like the venerable cough suppressant dextromethorphan found in Robitussin ...
The dose of bupropion in the study was lower than the target dose recommended for clinical practice. [10] In this study, dextromethorphan/bupropion showed significantly greater improvement than bupropion alone in the first two weeks of treatment but not by week 6 of treatment in people with major depressive disorder.
Quinidine prevents the metabolism of dextromethorphan into its active metabolite dextrorphan, which is a much more potent NMDA receptor antagonist but much less potent serotonin reuptake inhibitor than dextromethorphan. [6] [3] The mechanism of action of dextromethorphan/quinidine in the treatment of PBA is unknown. [3]